Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer

Neuroendocrine prostate cancer (NEPC) is a rare but aggressive histologic variant of prostate cancer that responds poorly to androgen deprivation therapy. Hybrid NEPC‐adenocarcinoma (AdCa) tumors are common, often eluding accurate pathologic diagnosis and requiring ancillary markers for classification. We recently performed an outlier‐based meta‐analysis across a number of independent gene expression microarray datasets to identify novel markers that differentiate NEPC from AdCa, including up‐regulation of insulinoma‐associated protein 1 (INSM1) and loss of Yes‐associated protein 1 (YAP1). Here, using diverse cancer gene expression datasets, we show that Hippo pathway‐related genes, including YAP1, are among the top down‐regulated gene sets with expression of the neuroendocrine transcription factors, including INSM1. In prostate cancer cell lines, transgenic mouse models, and human prostate tumor cohorts, we confirm that YAP1 RNA and YAP1 protein expression are silenced in NEPC and demonstrate that the inverse correlation of INSM1 and YAP1 expression helps to distinguish AdCa from NEPC. Mechanistically, we find that YAP1 loss in NEPC may help to maintain INSM1 expression in prostate cancer cell lines and we further demonstrate that YAP1 silencing likely occurs epigenetically, via CpG hypermethylation near its transcriptional start site. Taken together, these data nominate two additional markers to distinguish NEPC from AdCa and add to data from other tumor types suggesting that Hippo signaling is tightly reciprocally regulated with neuroendocrine transcription factor expression. © 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  J. Sage.  Faculty Opinions recommendation of SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: A comprehensive immunohistochemical and histopathologic characterization. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[2]  P. Meltzer,et al.  Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets , 2020, Clinical Epigenetics.

[3]  D. Cao,et al.  Expression of novel neuroendocrine marker insulinoma-associated protein 1 (INSM1) in genitourinary high-grade neuroendocrine carcinomas: An immunohistochemical study with specificity analysis and comparison to chromogranin, synaptophysin, and CD56. , 2020, Pathology, research and practice.

[4]  R. Shi,et al.  The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer , 2019, bioRxiv.

[5]  P. Nelson,et al.  Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. , 2019, The Journal of clinical investigation.

[6]  W. Isaacs,et al.  Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. , 2019, JCO precision oncology.

[7]  Yi Mi Wu,et al.  Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.

[8]  C. Rudin,et al.  Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data , 2019, Nature Reviews Cancer.

[9]  Yonggang Zheng,et al.  Nerfin-1 represses transcriptional output of Hippo signaling in cell competition , 2019, eLife.

[10]  W. Isaacs,et al.  Lactoferrin CpG Island Hypermethylation and Decoupling of mRNA and Protein Expression in the Early Stages of Prostate Carcinogenesis. , 2018, The American journal of pathology.

[11]  A. Sboner,et al.  CD38 is methylated in prostate cancer and regulates extracellular NAD+ , 2018, Cancer & Metabolism.

[12]  Yanqing Wang,et al.  Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. , 2018, Human pathology.

[13]  Joshua M. Stuart,et al.  Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Antonarakis,et al.  p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer , 2018, Prostate Cancer and Prostatic Diseases.

[15]  Wenchao Zhao,et al.  YAP knockdown inhibits proliferation and induces apoptosis of human prostate cancer DU145 cells. , 2017, Molecular medicine reports.

[16]  J. Bishop,et al.  INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors , 2018, The American journal of surgical pathology.

[17]  E. Davicioni,et al.  Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma , 2017, BMC Cancer.

[18]  Michael D. Nyquist,et al.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.

[19]  P. Worley,et al.  mTORC1 loss impairs epidermal adhesion via TGF-&bgr;/Rho kinase activation , 2017, The Journal of clinical investigation.

[20]  M. Rugge,et al.  MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinical–pathological features and outcome , 2017, Virchows Archiv.

[21]  V. Velcheti,et al.  Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer , 2017, Oncotarget.

[22]  P. Illei,et al.  INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity , 2017, The American journal of surgical pathology.

[23]  Jiaoti Huang,et al.  FOXA2 is a Sensitive and Specific marker for Small Cell Neuroendocrine Carcinoma of the Prostate , 2017, Modern Pathology.

[24]  P. Nelson,et al.  LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics , 2017, The Prostate.

[25]  T. Kameya,et al.  A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases. , 2017, Gynecologic oncology.

[26]  Faqian Li,et al.  mASH1 is Highly Specific for Neuroendocrine Carcinomas: An Immunohistochemical Evaluation on Normal and Various Neoplastic Tissues. , 2017, Archives of pathology & laboratory medicine.

[27]  C. Collins,et al.  SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. , 2017, European urology.

[28]  Hiroshi I. Suzuki,et al.  YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer , 2016, Cancer science.

[29]  S. Ishikawa,et al.  Loss of YAP1 defines neuroendocrine differentiation of lung tumors , 2016, Cancer science.

[30]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[31]  T. Buhl,et al.  NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas , 2015, International journal of cancer.

[32]  L. Chin,et al.  Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. , 2016, Cancer discovery.

[33]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[34]  R. Lloyd,et al.  INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms. , 2015, American journal of clinical pathology.

[35]  R. Vessella,et al.  Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas , 2015, Clinical Cancer Research.

[36]  M. Karin,et al.  A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis , 2015, Genes & development.

[37]  P. Nelson,et al.  SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.

[38]  P. Nelson,et al.  ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors. , 2015, Cancer cell.

[39]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[40]  M. Rubin,et al.  Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.

[41]  M. Rubin,et al.  High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. , 2014, Cancer research.

[42]  Wennuan Liu,et al.  Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma , 2013, Clinical Cancer Research.

[43]  M. Raffeld,et al.  Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma. , 2013, Experimental and molecular pathology.

[44]  Robert Gentleman,et al.  Software for Computing and Annotating Genomic Ranges , 2013, PLoS Comput. Biol..

[45]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[46]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[47]  J. Hicks,et al.  An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy , 2012, Cancer.

[48]  Robert H. Bell,et al.  From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer , 2012, The Journal of pathology.

[49]  Sven Laur,et al.  Robust rank aggregation for gene list integration and meta-analysis , 2012, Bioinform..

[50]  Robert C. Thompson,et al.  Negative regulation of Yap during neuronal differentiation. , 2012, Developmental biology.

[51]  Jindan Yu,et al.  Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. , 2012, Genes & development.

[52]  M. Gerstein,et al.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. , 2011, Cancer discovery.

[53]  Y. Yatabe,et al.  Molecular and Cellular Pathobiology Mir-375 Is Activated by Ash1 and Inhibits Yap1 in a Lineage-dependent Manner in Lung Cancer , 2022 .

[54]  Martin J. Aryee,et al.  Chromosome-wide mapping of DNA methylation patterns in normal and malignant prostate cells reveals pervasive methylation of gene-associated and conserved intergenic sequences , 2011, BMC Genomics.

[55]  C. Bieberich,et al.  ERG gene rearrangements are common in prostatic small cell carcinomas , 2011, Modern Pathology.

[56]  J. Cuzick,et al.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.

[57]  H. Rui,et al.  RB-pathway disruption in breast cancer , 2010, Cell cycle.

[58]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[59]  R. Kolde,et al.  Mining for coexpression across hundreds of datasets using novel rank aggregation and visualization methods , 2009, Genome Biology.

[60]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[61]  E. Montgomery,et al.  Expression of Yes-associated protein in common solid tumors. , 2008, Human pathology.

[62]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[63]  Li Li,et al.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. , 2007, Genes & development.

[64]  A. DeMarzo,et al.  Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation , 2006, Nucleic acids research.

[65]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[66]  M. Campbell,et al.  PANTHER: a library of protein families and subfamilies indexed by function. , 2003, Genome research.

[67]  Tsuey-Ming Chen,et al.  Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model , 2003, The Prostate.

[68]  J. Quinn,et al.  A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. , 2000, Cancer research.